Release date: 2017-01-16
Jianke CEO Xie Fangmin revealed that Jianke has set up a 200-person R&D center in Beijing to comprehensively upgrade the company's technology and products, and the newly joined Guanchong team leader. Xie Fangmin said that he is very much looking forward to Mr. Guan Chong's participation in the company. Through the improvement of technology and products, he will continue to strengthen the status of leading pharmaceutical e-commerce in China and contribute to the mobile medical sector. 
"Technology is the foundation of the development of e-commerce Internet companies. To meet the needs of current users, we must upgrade the technology level." Xie Fangmin believes that the current profit model of mobile medical care is still in the exploration stage, and the profitability of mobile medical care is still in the process of mining. And the combination with medical e-commerce, can quickly achieve the "medical" and "medicine" closed-loop, "medicine with medicine." He believes that mobile medical must be combined with medical e-commerce to have a future.
Jianke started out as a medical e-commerce company and just got a $100 million financing in the A round in early 2016. In recent years, it has also started to get involved in the mobile medical sector. In July 2016, its mobile medical sector APP was officially renamed as “Jianke Doctorâ€. Xie Fangmin has publicly stated that in 2016, the turnover of Jianke was 1.5 billion yuan, a year-on-year increase of 50%; in 2015, the annual turnover was 1 billion yuan, ranking second among online pharmacies nationwide.
Xie Fangmin revealed that Jianke's 2017 turnover will strive to complete the goal of 2.5 billion yuan, and has completed the layout of the Huazhong branch company and the Internet hospital project. It is reported that the former New Oriental CIO and the former handle network CTO officially joined the medical e-commerce. As a senior vice president of technology, he became a newcomer to join the company after joining the company's CEO, Zhou Feng, and becoming the company's executive director, chief strategy officer and chief financial officer.
Jianke CEO Xie Fangmin revealed that Jianke has set up a 200-person R&D center in Beijing to comprehensively upgrade the company's technology and products, and the newly joined Guanchong team leader. Xie Fangmin said that he is very much looking forward to Mr. Guan Chong's participation in the company. Through the improvement of technology and products, he will continue to strengthen the status of leading pharmaceutical e-commerce in China and contribute to the mobile medical sector.
"Technology is the foundation of the development of e-commerce Internet companies. To meet the needs of current users, we must upgrade the technology level." Xie Fangmin believes that the current profit model of mobile medical care is still in the exploration stage, and the profitability of mobile medical care is still in the process of mining. And the combination with medical e-commerce, can quickly achieve the "medical" and "medicine" closed-loop, "medicine with medicine." He believes that mobile medical must be combined with medical e-commerce to have a future.
Jianke started out as a medical e-commerce company and just got a $100 million financing in the A round in early 2016. In recent years, it has also started to get involved in the mobile medical sector. In July 2016, its mobile medical sector APP was officially renamed as “Jianke Doctorâ€. Xie Fangmin has publicly stated that in 2016, the turnover of Jianke was 1.5 billion yuan, a year-on-year increase of 50%; in 2015, the annual turnover was 1 billion yuan, ranking second among online pharmacies nationwide.
Xie Fangmin revealed that the 2017 turnover of Jianke will strive to complete the goal of 2.5 billion yuan, and will continue to complete the plan of the Huazhong branch company, the Internet hospital project layout, and gradually realize the strategic goal of the Jianke smart health platform. Plan to gradually realize the strategic goals of the Health Wisdom Smart Health Platform.
Source: Health Point
Semaglutide pen injector is a medical device used to administer semaglutide, a medication used to treat type 2 diabetes. The pen injector is a prefilled, disposable pen that contains a fixed dose of semaglutide. It is designed to make it easy for patients to self-administer the medication with a single injection once a week. The pen injector is equipped with a needle that is inserted into the skin of the abdomen, thigh, or upper arm to deliver the medication. The semaglutide pen injector is a convenient and effective way to manage type 2 diabetes, as it helps to regulate blood sugar levels and reduce the risk of complications associated with the condition.
Semaglutide Pen Injector,Disposbale Pen Injector,High Precision Pen Injector,Pen Injector For Subcutaneous
Shanghai Enjosim Medical Technology Co., Ltd , https://www.enjosimmedical.com